AI-Based TIL Analysis Predicts pCR in HR+/HER2– Breast Cancer
High Immune Gene Signature and sTILs Linked to Survival Outcomes in Stage I TNBC
Chemotherapy Declination Associated With Increased Risk of Death Among Patients With Early-Stage HR+/HER2- BC and High RS